AgomAb Therapeutics NV is a clinical-stage biotech company developing treatments for immunological and inflammatory conditions. Its pipeline includes an oral medication targeting a fibrosis-related pathway for Crohn's disease currently in Phase 2a trials, an inhaled version of a similar compound for pulmonary fibrosis in Phase 1 testing, and an antibody candidate designed to stimulate tissue repair mechanisms that has shown promise in preclinical studies. The company was founded in 2017 and operates from Belgium.

entry readiness 91 · STRONG SETUP · exit proximity 0

Value area 10.33–14.08 · 96% of 120d volume overhead · heavy supply